Cargando…
In-silico studies of inhibitory compounds against protease enzymes of SARS-CoV-2
In December 2019, a COVID-19 outbreak caused by SARS-CoV-2 raised worldwide health concerns. In this case, molecular docking and drug repurposing computational approaches were engaged to check the efficiency of plant-based inhibitory compounds against SARS-CoV-2 main protease enzyme and papain-like...
Autores principales: | Khan, Saba, Nasrullah, Hussain, Abrar, Asif, Muhammad, Sattar, Fouzia Abdul, Audhal, Fayyaz Ahmed, Qadir, Muhammad Imran, Hamdard, Muhammad Hamid |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9907915/ https://www.ncbi.nlm.nih.gov/pubmed/36820539 http://dx.doi.org/10.1097/MD.0000000000031318 |
Ejemplares similares
-
Luteolin is a potential inhibitor of COVID-19: An in silico analysis
por: Wang, Wenxiang, et al.
Publicado: (2023) -
First clinical study using HCV protease inhibitor danoprevir to treat COVID-19 patients
por: Chen, Hongyi, et al.
Publicado: (2020) -
Pattern of antibiotic use for acute respiratory infections among out-patients in South Asian Region: Protocol for a systematic review
por: Al-Amin, Saif, et al.
Publicado: (2021) -
Role of tocilizumab for concomitant systemic fungal infection in severe COVID-19 patient: Case report
por: Sari, Anggraini Permata, et al.
Publicado: (2021) -
The role of early blood purification for miliary tuberculosis presenting as acute respiratory distress syndrome in pregnancy: A case report
por: Sari, Anggraini Permata, et al.
Publicado: (2023)